Duquesne Family Office LLC Purchases 512,825 Shares of NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• Duquesne Family Office LLC increased its stake in NewAmsterdam Pharma by 178.4%, acquiring an additional 512,825 shares, totaling 800,360 shares worth approximately $16.4 million.
• Several large investors, including Mirae Asset Global Investments and HB Wealth Management, have recently increased their holdings in NewAmsterdam Pharma, indicating strong institutional interest with 89.89% of the company's stock owned by institutional investors.
• NewAmsterdam Pharma's stock received positive analyst ratings, with a consensus price target of $41.55 and multiple brokerages issuing "buy" and "outperform" ratings as of recent reports.

Duquesne Family Office LLC lifted its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 178.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 800,360 shares of the company's stock after purchasing an additional 512,825 shares during the period. Duquesne Family Office LLC owned about 0.73% of NewAmsterdam Pharma worth $16,383,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of NewAmsterdam Pharma by 19.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after purchasing an additional 596 shares during the last quarter. Quarry LP acquired a new position in shares of NewAmsterdam Pharma in the first quarter worth about $25,000. GF Fund Management CO. LTD. acquired a new position in shares of NewAmsterdam Pharma in the fourth quarter worth about $50,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of NewAmsterdam Pharma by 12.5% in the first quarter. China Universal Asset Management Co. Ltd. now owns 22,028 shares of the company's stock worth $451,000 after buying an additional 2,439 shares during the period. Finally, HB Wealth Management LLC boosted its holdings in shares of NewAmsterdam Pharma by 28.9% in the first quarter. HB Wealth Management LLC now owns 11,247 shares of the company's stock worth $230,000 after buying an additional 2,519 shares during the period. Institutional investors and hedge funds own 89.89% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Cantor Fitzgerald started coverage on shares of NewAmsterdam Pharma in a report on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 target price for the company. Stifel Nicolaus started coverage on NewAmsterdam Pharma in a research report on Tuesday, June 10th. They issued a "buy" rating and a $44.00 target price for the company. The Goldman Sachs Group started coverage on NewAmsterdam Pharma in a research report on Thursday, July 17th. They issued a "neutral" rating and a $27.00 target price for the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, June 12th. Finally, Wells Fargo & Company started coverage on NewAmsterdam Pharma in a research report on Monday, August 25th. They issued an "overweight" rating and a $45.00 target price for the company. Nine research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, NewAmsterdam Pharma currently has an average rating of "Moderate Buy" and a consensus price target of $41.55.

NewAmsterdam Pharma Trading Up 4.1%

NASDAQ NAMS traded up $1.03 during trading on Tuesday, hitting $26.12. 775,062 shares of the company traded hands, compared to its average volume of 881,196. NewAmsterdam Pharma Company N.V. has a 12 month low of $14.06 and a 12 month high of $27.29. The business has a fifty day simple moving average of $23.12 and a 200 day simple moving average of $20.62. The company has a market capitalization of $2.94 billion, a P/E ratio of -16.13 and a beta of -0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.37. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. The firm had revenue of $19.15 million during the quarter, compared to the consensus estimate of $1.44 million. Equities research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, Director James N. Topper bought 2,520 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, June 24th. The shares were bought at an average price of $18.43 per share, with a total value of $46,443.60. Following the purchase, the director owned 3,024,873 shares of the company's stock, valued at $55,748,409.39. This trade represents a 0.08% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CAO Louise Frederika Kooij sold 18,073 shares of NewAmsterdam Pharma stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $25.09, for a total transaction of $453,451.57. Following the transaction, the chief accounting officer directly owned 15,000 shares in the company, valued at $376,350. The trade was a 54.65% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders bought 12,835 shares of company stock worth $248,134 and sold 274,954 shares worth $5,899,406. 20.84% of the stock is currently owned by insiders.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.